By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders could eliminate KRAS and redefine cancer care – insights from Astellas’ Head of Oncology Development
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule…
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
How can timely, precise lab data improve decision-making across the medicine lifecycle? Download this whitepaper to explore how…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
